In summary, while rapamycin is a potent inhibitor of the mTORC1-driven S6K/S6 pathway in LAM cells it is less effective against the tumorigenic 4E-BP/eIF4E pathway. This evidence concerns the gene RPS6KB1 and lymphangioleiomyomatosis.